Should I Buy SLNO? SLNO 2026 Analysis

Should You Buy Soleno Therapeutics Inc (SLNO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

39.040

1 Day change

-3.72%

52 Week Range

90.320

Analysis Updated At

2026/01/26

Based on the data provided, Soleno Therapeutics Inc (SLNO) does not present a strong buy opportunity for a beginner investor with a long-term strategy. While there are positive aspects such as analyst optimism and strong gross margins, the significant insider selling, ongoing legal investigations, and weak financial performance indicate caution. Holding off on investment until clearer positive catalysts emerge would be prudent.

Technical Analysis

The technical indicators show a mixed picture. The MACD is positive but contracting, RSI is neutral at 37.24, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 42.648, with resistance at 45.112 and support at 40.184. Overall, the technical trend does not strongly favor a buy.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market, but this alone is not enough to offset other concerns.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have raised price targets recently, with Wells Fargo and H.C. Wainwright setting targets of $114 and $120, respectively, citing strong sales performance and free cash flow potential.
Gross margin remains high at 98.27%.

Neutral/Negative Catalysts

Insider selling has increased significantly (1314.42% over the last month), which raises concerns about management's confidence in the stock.
Legal investigations into potential securities law violations following a 40% stock price decline.
Weak financial performance in Q3 2025, with net income dropping by -133.95% YoY and EPS falling by -125.68% YoY.
Concerns about the company's reliance on a single product with expiring intellectual property, as highlighted by a short-seller report.

Financial Performance

In Q3 2025, revenue remained flat at $66.02M (0.00% YoY), while net income dropped significantly to $26.01M (-133.95% YoY). EPS also fell sharply to 0.47 (-125.68% YoY). Despite a high gross margin of 98.27%, the financial performance is weak overall.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are optimistic, with recent upgrades in price targets (e.g., $114 and $120) and positive commentary on sales performance. However, concerns about patient start forms and competition remain. Wolfe Research initiated coverage with an Outperform rating, citing favorable utilization trends despite safety concerns.

8 Analyst Rating

Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 110.5 USD with a low forecast of 75 USD and a high forecast of 125 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 40.550

Low

Averages

110.5

High

125

Current: 40.550

Low

Averages

110.5

High

125

Wells Fargo

Derek Archila

Overweight

maintain

$106 -> $114

AI Analysis

2026-01-20

Reason

Wells Fargo

Derek Archila

Price Target

$106 -> $114

AI Analysis

2026-01-20

maintain

Overweight

Reason

Wells Fargo analyst Derek Archila raised the firm's price target on Soleno Therapeutics to $114 from $106 and keeps an Overweight rating on the shares. The firm notes Q4 Vykat extended-release revenues beat, with an acceptable discontinuation rate due to adverse events. While patient start forms fell short, management's commentary last week reinforced about 250 PSFs per quarter at steady state, absent seasonal factors. Management will need to deliver on this, but Wells doesn't think Street's FY26 estimates seem aggressive and shares trade at a meaningful discount given its free cash flow profile.

H.C. Wainwright

Buy

maintain

$110 -> $120

2026-01-20

Reason

H.C. Wainwright

Price Target

$110 -> $120

2026-01-20

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Soleno Therapeutics to $120 from $110 and keeps a Buy rating on the shares. The firm says the company's sales continue to outperform its estimates.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SLNO

Unlock Now

SLNO Should I Buy

SLNO Should I Buy

Should You Buy Soleno Therapeutics Inc (SLNO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch